Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Johnson and Johnson
Accenture
Farmers Insurance
US Army
Cerilliant
Covington
Deloitte
Fuji

Generated: October 18, 2017

DrugPatentWatch Database Preview

Galantamine hydrobromide - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for galantamine hydrobromide and what is the scope of galantamine hydrobromide patent protection?

Galantamine hydrobromide
is the generic ingredient in three branded drugs marketed by Mylan, Yabao Pharm, Barr, West-ward Pharms Int, Janssen Pharms, Watson Labs, Aurobindo Pharma Ltd, Sun Pharma Global, Apotex Inc, Impax Labs, Actavis Elizabeth, Teva Pharms, Sandoz, Dr Reddys Labs Ltd, and Zydus Pharms Usa Inc, and is included in twenty-two NDAs. There are three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Galantamine hydrobromide has eighty-nine patent family members in thirty-five countries and one supplementary protection certificate in one country.

There are fifteen drug master file entries for galantamine hydrobromide. Twenty-one suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: galantamine hydrobromide

US Patents:3
Tradenames:3
Applicants:15
NDAs:22
Drug Master File Entries: see list15
Suppliers / Packagers: see list21
Bulk Api Vendors: see list56
Clinical Trials: see list148
Patent Applications: see list571
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:galantamine hydrobromide at DailyMed

Pharmacology for Ingredient: galantamine hydrobromide

Tentative approvals for GALANTAMINE HYDROBROMIDE

Applicant Application No. Strength Dosage Form
u► Subscribe4MGTABLET; ORAL
u► Subscribe12MGTABLET; ORAL
u► Subscribe8MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Ltd
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL077593-001Sep 11, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Impax Labs
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL078484-001May 27, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Ltd
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL077593-003Sep 11, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Barr
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL077605-001Aug 28, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Yabao Pharm
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL077604-002Feb 6, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Barr
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL078189-003Sep 15, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL090178-001Feb 2, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa Inc
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL078898-002Feb 17, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
West-ward Pharms Int
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL077608-003Feb 11, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
GALANTAMINE HYDROBROMIDE
galantamine hydrobromide
TABLET;ORAL077781-003Sep 27, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: galantamine hydrobromide

International Patent Family for Ingredient: galantamine hydrobromide

Country Document Number Estimated Expiration
European Patent Office1140105► Subscribe
Ukraine79578► Subscribe
Spain2211215► Subscribe
Norway985815► Subscribe
Brazil9709729► Subscribe
World Intellectual Property Organization (WIPO)9747304► Subscribe
Canada2358062► Subscribe
Brazil9916835► Subscribe
Portugal1140105► Subscribe
Japan2000511918► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: GALANTAMINE HYDROBROMIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00140Netherlands► SubscribePRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Express Scripts
US Army
Cipla
Baxter
Deloitte
QuintilesIMS
Cantor Fitzgerald
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot